Objective To explore the influence of camrelizumab combined with platinum-containing dual-drug regimen in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods The clinical data of patients with NSCLC in the hospital were retrospectively analyzed from January 2019 to January 2021. 53 patients who were treated with pemetrexed and carboplatin were randomly selected and included in control group, and 53 patients receiving camrelizumab combined with platinum-containing dual-drug regimen were enrolled as observation group. The clinical symptom relief rate after 3 courses of treatment and occurrence of toxic and side effects during treatment were recorded. The changes in immune function (CD3+, CD4+, CD8+, CD4+/CD8+ratio), serum tumor markers ［neuron-specific enolase (NSE), carcinoembryonic antigen (CEA)］and quality of life ［Quality of Life Questionnaire-Lung Cancer (QLQ-LC43)］ were compared between the two groups before treatment and after 3 courses of treatment. Follow-up was conducted for 2 years after chemotherapy, and the long-term efficacy was compared. Results After 3 courses of treatment, the symptom relief rate and 2-year survival rate in observation group were significantly higher than those in control group (P＜0.05), but there were no statistical differences in the incidence rates of toxic and side effects (P＞0.05). The CD3+, CD4+and CD4+/CD8+level in both groups were decreased after 3 courses of treatment, and the indicators in observation group were higher than those in control group (P＜0.05), and the CD8+ level and QLQ-LC43 score were increased, and the indicators in observation group were lower than those in control group (P＜0.05). After 3 courses of treatment, serum NSE and CEA were declined in both groups, and the levels in observation group were lower than those in control group (P＜0.05). After 2 years of follow-up, the mortality rate in observation group (11.32%) was significantly lower than that in control group (26.42%) (P＜0.05), and the PFS with (9.37±1.24) months was significantly longer than (7.83±0.95) months in control group (P＜0.05), and the OS with (12.57±1.58) months was significantly longer compared with (9.61±1.39) months in control group (P＜0.05).Conclusion Camrelizumab combined with platinum-containing dual-drug regimen has significant clinical efficacy on patients with NSCLC, and it can effectively reduce the levels of serum tumor markers, enhance the body immunity, and help to improve the long-term survival rate of patients